Exploration of Medicine

Table 3. Top associations for time to CD

Chr	BP	rsID	A1	A2	Gene	Group	Yale-Penn				COGA		Yale-Penn + COGA
Chr	BP	rsID	A1	A2	Gene	Group	MAF	AA P	EA P	AA + EA P	AA P	EA P	HR	P	Direction
1	166038842	rs61835088	T	C	FAM78B	All	0.14	5.19 E-08	2.55 E-02	2.96 E-08	0.89	0.01	0.87	3.71 E-09	--------
5	170894319	rs112894747	C	G	FGF18-LOC105377721	AA	0.03	9.01 E-06	NA	9.01 E-06	0.01	NA	1.41	4.76 E-07	+-++
7	90978616	rs74426341	C	G	LOC105375392	All	0.04	1.46 E-06	5.70 E-07	1.46 E-06	0.08	0.62	1.37	2.52 E-07	?+- +++++
7	90983464	rs73404786	A	G	LOC105375392	EA	0.04	2.75 E-01	5.20 E-08	4.19 E-07	0.08	0.74	1.38	2.37 E-07	++++
7	121807926	rs73721103	T	G	AASSLOC102724527	AA	0.05	6.57 E-01	NA	2.76 E-03	0.11	NA	1.30	4.00 E-07	++++
21	20404237	rs2825295	T	G	AL157359.3-AP000431.1	AA	0.35	1.45 E-07	3.15 E-02	1.04 E-07	0.07	0.83	1.14	2.57 E-08	++++

Return to article view

The order of the symbols corresponds to Yale-Penn 1, Yale Penn 2, Yale-Penn 3, COGA. If AAs and EAs are combined, the AA symbol precedes the EA symbol. A1: effect allele; A2: non-effect allele; MAF: minor allele frequency in the subset of the Yale-Penn cohort indicated in the Group column; P: P-value; Direction: effect direction of A1

Supplementary materials

The supplementary materials for this article are available at:

https://www.explorationpub.com/uploads/Article/file/100132_sup_1.pdf

Declarations

Author contributions

JG, LAF, HRK, HJE, EN, NGM, and LD contributed conception and design of the study; CZ, EJ, and LW, and RS performed the statistical analysis; RS wrote the first draft of the manuscript; all authors contributed to manuscript revision, read and approved the submitted version.

Conflicts of interest

Dr. Kranzler is a member of an advisory board for Dicerna Pharmaceuticals and a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative (ACTIVE Group), which over the past three years was supported by Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Ethypharm, Indivior, Lundbeck, Mitsubishi, and Otsuka. Drs. Kranzler and Gelernter are named as inventors on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists”, filed January 24, 2018. In the past three years, Dr. Degenhardt has received untied educational grant funding from Indivior and Seqirus. No other authors reported potential conflicts of interest.

Ethical approval

This study was approved by the Institutional Review Boards of Boston University, Yale University and the University of Pennsylvania.

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

Summary statistics for GWAS analyses will be provided by the corresponding author upon request.

Funding

This study was supported by National Institutes of Health grants RC2 DA028909, R01 DA12690, R01 DA12849, R01 DA18432, R01 AA11330, R01 AA017535, 2P50-AA012870, VA Connecticut Healthcare Center, Philadelphia VA MIRECCS, and National Center for Post Traumatic Stress Disorder. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

GBD 2016 Alcohol and Drug Use Collaborators. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5:987–1012. [DOI] [PubMed] [PMC]

Rummans TA, Burton MC, Dawson NL. How good intentions contributed to bad outcomes: the opioid crisis. Mayo Clin Proc. 2018;93:344–50. [DOI] [PubMed]

Case A, Deaton A. Mortality and morbidity in the 21st century. Brookings Pap Econ Act. 2017;2017: 397–476. [DOI] [PubMed] [PMC]

Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet. 2019;394:1560–79. [DOI] [PubMed] [PMC]

Clark CB, Zyambo CM, Li Y, Cropsey KL. The impact of non-concordant self-report of substance use in clinical trials research. Addict Behav. 2016;58:74–9. [DOI] [PubMed] [PMC]

Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2007;64:566–76. [DOI] [PubMed]

Degenhardt L, Singleton J, Calabria B, McLaren J, Kerr T, Mehta S, et al. Mortality among cocaine users: a systematic review of cohort studies. Drug Alcohol Depend. 2011;113:88–95. [DOI] [PubMed]

Roy A. Characteristics of cocaine dependent patients who attempt suicide. Arch Suicide Res. 2009;13: 46–51. [DOI] [PubMed]

Chan B, Kondo K, Freeman M, Ayers C, Montgomery J, Kansagara D. Pharmacotherapy for cocaine use disorder-a systematic review and meta-analysis. J Gen Intern Med. 2019;34:2858–73. [DOI] [PubMed] [PMC]

10.

Mistry CJ, Bawor M, Desai D, Marsh DC, Samaan Z. Genetics of opioid dependence: a review of the genetic contribution to opioid dependence. Curr Psychiatry Rev. 2014;10:156–67. [DOI] [PubMed] [PMC]

11.

Kendler KS, Karkowski LM, Neale MC, Prescott CA. Illicit psychoactive substance use, heavy use, abuse, and dependence in a US population-based sample of male twins. Arch Gen Psychiatry. 2000;57:261–9. [DOI] [PubMed]

12.

Kendler KS, Prescott CA. Cocaine use, abuse and dependence in a population-based sample of female twins. Br J Psychiatry. 1998;173:345–50. [DOI] [PubMed]

13.

Gelernter J, Kranzler HR, Sherva R, Koesterer R, Almasy L, Zhao H, et al. Genome-wide association study of opioid dependence: multiple associations mapped to calcium and potassium pathways. Biol Psychiatry. 2014;76:66–74. [DOI] [PubMed] [PMC]

14.

Cheng Z, Zhou H, Sherva R, Farrer LA, Kranzler HR, Gelernter J. Genome-wide association study identifies a regulatory variant of RGMA associated with opioid dependence in European Americans. Biol Psychiatry. 2018;84:762–70. [DOI] [PubMed] [PMC]

15.

Nelson EC, Agrawal A, Heath AC, Bogdan R, Sherva R, Zhang B, et al. Evidence of CNIH3 involvement in opioid dependence. Mol Psychiatry. 2016;21:608–14. [DOI] [PubMed] [PMC]

16.

Polimanti R, Walters RK, Johnson EC, McClintick JN, Adkins AE, Adkins DE, et al. Leveraging genome-wide data to investigate differences between opioid use vs. opioid dependence in 41,176 individuals from the Psychiatric Genomics Consortium. Mol Psychiatry. 2020;25:1673–87. [DOI] [PubMed] [PMC]

17.

Cabana-Dominguez J, Shivalikanjli A, Fernandez-Castillo N, Cormand B. Genome-wide association meta-analysis of cocaine dependence: shared genetics with comorbid conditions. Prog Neuropsychopharmacol Biol Psychiatry. 2019;94:109667. [DOI] [PubMed]

18.

Gelernter J, Sherva R, Koesterer R, Almasy L, Zhao H, Kranzler HR, et al. Genome-wide association study of cocaine dependence and related traits: FAM53B identified as a risk gene. Mol Psychiatry. 2014;19:717–23. [DOI] [PubMed] [PMC]

19.

Zhou H, Rentsch CT, Cheng Z, Kember RL, Nunez YZ, Sherva RM, et al. Association of OPRM1 functional coding variant with opioid use disorder: a genome-wide association study. JAMA Psychiatry. 2020;77:1072–80. [DOI]

20.

Smith AH, Jensen KP, Li J, Nunez Y, Farrer LA, Hakonarson H, et al. Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1. Mol Psychiatry. 2017;22:346–52. [DOI] [PubMed] [PMC]

21.

Anthony J, Warner L, Kessler R. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol. 1994;2:244–68.

22.

Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers-United States, 2002–2004 and 2008–2010. Drug Alcohol Depend. 2013;132:95–100. [DOI] [PubMed]

23.

Reboussin BA, Anthony JC. Is there epidemiological evidence to support the idea that a cocaine dependence syndrome emerges soon after onset of cocaine use? Neuropsychopharmacology. 2006;31:2055–64. [DOI] [PubMed] [PMC]

24.

Sartor CE, Kranzler HR, Gelernter J. Rate of progression from first use to dependence on cocaine or opioids: a cross-substance examination of associated demographic, psychiatric, and childhood risk factors. Addict Behav. 2014;39:473–9. [DOI] [PubMed] [PMC]

25.

Associations of nonmedical pain reliever use and initiation of heroin use in the United States [Internet]. Rockville: Substance Abuse and Mental Health Services Administration; c2013 [cited 2020 Dec 1]. Available from: https://www.samhsa.gov/data/sites/default/files/DR006/DR006/nonmedical-pain-reliever-use-2013.htm

26.

Gelernter J, Panhuysen C, Weiss R, Brady K, Hesselbrock V, Rounsaville B, et al. Genomewide linkage scan for cocaine dependence and related traits: significant linkages for a cocaine-related trait and cocaine-induced paranoia. Am J Med Genet B Neuropsychiatr Genet. 2005;136B:45–52. [DOI] [PubMed]

27.

Sherva R, Wang Q, Kranzler H, Zhao H, Koesterer R, Herman A, et al. Genome-wide association study of cannabis dependence severity, novel risk variants, and shared genetic risks. JAMA Psychiatry. 2016;73:472–80. [DOI] [PubMed] [PMC]

28.

Pierucci-Lagha A, Gelernter J, Chan G, Arias A, Cubells JF, Farrer L, et al. Reliability of DSM-IV diagnostic criteria using the semi-structured assessment for drug dependence and alcoholism (SSADDA). Drug Alcohol Depend. 2007;91:85–90. [DOI] [PubMed] [PMC]

29.

Malison RT, Kalayasiri R, Sanichwankul K, Sughondhabirom A, Mutirangura A, Pittman B, et al. Inter-rater reliability and concurrent validity of DSM-IV opioid dependence in a Hmong isolate using the Thai version of the Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA). Addict Behav. 2011;36:156–60. [DOI] [PubMed] [PMC]

30.

Nelson EC, Lynskey MT, Heath AC, Wray N, Agrawal A, Shand FL, et al. Association of OPRD1 polymorphisms with heroin dependence in a large case-control series. Addict Biol. 2014;19:111–21. [DOI] [PubMed] [PMC]

31.

Nelson EC, Lynskey MT, Heath AC, Wray N, Agrawal A, Shand FL, et al. ANKK1, TTC12, and NCAM1 polymorphisms and heroin dependence: importance of considering drug exposure. JAMA Psychiatry. 2013;70:325–33. [DOI] [PubMed] [PMC]

32.

Bucholz KK, Cadoret R, Cloninger CR, Dinwiddie SH, Hesselbrock VM, Nurnberger JI Jr, et al. A new, semi-structured psychiatric interview for use in genetic linkage studies: a report on the reliability of the SSAGA. J Stud Alcohol. 1994;55:149–58. [DOI] [PubMed]

33.

Edenberg HJ. The collaborative study on the genetics of alcoholism: an update. Alcohol Res Health. 2002;26:214–8. [PubMed] [PMC]

34.

Reich T, Edenberg HJ, Goate A, Williams JT, Rice JP, Van Eerdewegh P, et al. Genome-wide search for genes affecting the risk for alcohol dependence. Am J Med Genet. 1998;81:207–15. [PubMed]

35.

Hesselbrock M, Easton C, Bucholz KK, Schuckit M, Hesselbrock V. A validity study of the SSAGA--a comparison with the SCAN. Addiction. 1999;94:1361–70. [DOI] [PubMed]

36.

Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet. 2012;44:955–9. [DOI] [PubMed] [PMC]

37.

Wetherill L, Lai D, Johnson EC, Anokhin A, Bauer L, Bucholz KK, et al. Genome-wide association study identifies loci associated with liability to alcohol and drug dependence that is associated with variability in reward-related ventral striatum activity in African- and European-Americans. Genes Brain Behav. 2019;18:e12580. [DOI] [PubMed] [PMC]

38.

Delaneau O, Marchini J, Zagury JF. A linear complexity phasing method for thousands of genomes. Nat Methods. 2011;9:179–81. [DOI] [PubMed]

39.

Das S, Forer L, Schönherr S, Sidore C, Locke AE, Kwong J, et al. Next-generation genotype imputation service and methods. Nat Genet. 2016;48:1284–7. [DOI] [PubMed] [PMC]

40.

Cox DR. Regression models and life-tables. J R Stat Soc Series B Stat Methodol. 1972;34:187–220. [DOI]

41.

Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26:2190–1. [DOI] [PubMed] [PMC]

42.

Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. Nat Commun. 2017;8:1826. [DOI] [PubMed] [PMC]

43.

Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics. 2010;26:2336–7. [DOI] [PubMed] [PMC]

44.

Fan N, An L, Zhang M, He H, Zhou Y, Ou Y. GRIN2B gene polymorphism in chronic ketamine users. Am J Addict. 2020;29:105–10. [DOI] [PubMed]

45.

Xie P, Kranzler HR, Krystal JH, Farrer LA, Zhao H, Gelernter J. Deep resequencing of 17 glutamate system genes identifies rare variants in DISC1 and GRIN2B affecting risk of opioid dependence. Addict Biol. 2014;19:955–64. [DOI] [PubMed] [PMC]

46.

Polimanti R, Zhang H, Smith AH, Zhao H, Farrer LA, Kranzler HR, et al. Genome-wide association study of body mass index in subjects with alcohol dependence. Addict Biol. 2017;22:535–49. [DOI] [PubMed] [PMC]

47.

Goodyear K, Lee MR, Schwandt ML, Hodgkinson CA, Leggio L. Hepatic, lipid and genetic factors associated with obesity: crosstalk with alcohol dependence? World J Biol Psychiatry. 2017;18:120–8. [DOI] [PubMed] [PMC]

48.

Sobczyk-Kopciol A, Broda G, Wojnar M, Kurjata P, Jakubczyk A, Klimkiewicz A, et al. Inverse association of the obesity predisposing FTO rs9939609 genotype with alcohol consumption and risk for alcohol dependence. Addiction. 2011;106:739–48. [DOI] [PubMed]

49.

Gramage E, Perez-Garcia C, Vicente-Rodriguez M, Bollen S, Rojo L, Herradon G. Regulation of extinction of cocaine-induced place preference by midkine is related to a differential phosphorylation of peroxiredoxin 6 in dorsal striatum. Behav Brain Res. 2013;253:223–31. [DOI] [PubMed]

50.

Gramage E, Putelli A, Polanco MJ, Gonzalez-Martin C, Ezquerra L, Alguacil LF, et al. The neurotrophic factor pleiotrophin modulates amphetamine-seeking behaviour and amphetamine-induced neurotoxic effects: evidence from pleiotrophin knockout mice. Addict Biol. 2010;15:403–12. [DOI] [PubMed]

51.

Zheng Z, Huang D, Wang J, Zhao K, Zhou Y, Guo Z, et al. QTLbase: an integrative resource for quantitative trait loci across multiple human molecular phenotypes. Nucleic Acids Research. 2019;48:D983–91. [DOI]

52.

Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics. 2014;13:397–406. [DOI]

53.

Huttlin EL, Bruckner RJ, Paulo JA, Cannon JR, Ting L, Baltier K, et al. Architecture of the human interactome defines protein communities and disease networks. Nature. 2017;545:505–9. [DOI] [PubMed] [PMC]

54.

Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607–13. [DOI] [PubMed] [PMC]

55.

Bayer KU, De Koninck P, Leonard AS, Hell JW, Schulman H. Interaction with the NMDA receptor locks CaMKII in an active conformation. Nature. 2001;411:801–5. [DOI] [PubMed]

56.

Claussnitzer M, Dankel SN, Kim KH, Quon G, Meuleman W, Haugen C, et al. FTO obesity variant circuitry and adipocyte browning in humans. N Engl J Med. 2015;373:895–907. [DOI] [PubMed] [PMC]

57.

Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316:889–94. [DOI] [PubMed] [PMC]

58.

Smemo S, Tena JJ, Kim KH, Gamazon ER, Sakabe NJ, Gomez-Marin C, et al. Obesity-associated variants within FTO form long-range functional connections with IRX3. Nature. 2014;507:371–5. [DOI] [PubMed] [PMC]

59.

Sevgi M, Rigoux L, Kuhn AB, Mauer J, Schilbach L, Hess ME, et al. An obesity-predisposing variant of the FTO gene regulates D2R-dependent reward learning. J Neurosci. 2015;35:12584–92. [DOI] [PubMed] [PMC]

60.

Gramage E, Vicente-Rodriguez M, Herradon G. Pleiotrophin modulates morphine withdrawal but has no effects on morphine-conditioned place preference. Neurosci Lett. 2015;604:75–9. [DOI] [PubMed]